US EditionSkyhawk Begins Dosing In Huntington's Disease Trial Of SKY-0515 - Data Intelligence
Summary by Plato. Vertical Search. Ai. | PlatoAiStream. Data Intelligence. Vertical Search. Ai.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Skyhawk Begins Dosing In Huntington's Disease Trial Of SKY-0515 - Data Intelligence
The trial aims to assess the therapy in individuals with Stage 2 and early Stage 3 Huntington’s disease. Credit: bangoland/Shutterstock. Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule RNA splicing modulator, SKY-0515, for Huntington’s disease (HD) treatment. The placebo-controlled, double-blind trial plans to enrol 120 individuals across New Zealand and Australia across …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
